ARIX — Arix Bioscience Income Statement
0.000.00%
Last trade - 00:00
- £183.80m
- £82.85m
- £0.11m
- 29
- 34
- 90
- 48
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.33 | 0.506 | 0.477 | 0.34 | 0.112 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 11.7 | 11 | 7.93 | 12.5 | 5.41 |
Operating Profit | -10.4 | -10.5 | -7.45 | -12.2 | -5.29 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 42.8 | -75.6 | 126 | -61.1 | -27.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | 36.9 | -69.7 | 126 | -61.1 | -27.6 |
Net Income Before Extraordinary Items | |||||
Net Income | 36.9 | -69.7 | 126 | -61.1 | -27.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 36.9 | -69.7 | 126 | -61.1 | -27.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.287 | -0.53 | 0.888 | -0.423 | -0.222 |